Loading data for BNTC — first visit, this takes a few seconds.

Preisalarm

Benitec Biopharma Inc. (BNTC)

NasdaqCM: BNTC · Echtzeitkurs · USD

12.54

+0.20 (1.62%)

Zum Schluss: Aug 18, 2026, 8:00 PM

1.62% (1D)

Keine Daten verfügbar

Geld	8.9
Marktkapitalisierung	442.48 Mio
Umsatz (TTM)	n/a
Nettogewinn (TTM)	-41.54 Mio
Beta	0.26
EPS (ttm)	-0.91
KGV (TTM)	n/a
Forward-KGV	-1.37
KBV (TTM)	2.41
KUV (TTM)	n/a
Earnings Date	Sep 22, 2026

Brief	16.01
Volumen	6,000
Ø Vol. (20D)	124,382
Eröffnung	12.40
Vortagesschluss	12.34
Tagesspanne	12.40 - 12.77
52-Wk Range	9.85 - 16.76
Analyst	n/a
Kursziel	n/a
Dividenden	n/a
Ex-Dividenden-Datum	n/a

Über BNTC

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The com...

[Mehr lesen]

Branche Biotechnology

Sektor Healthcare

IPO Datum Jun 24, 2014

Mitarbeiter 19

Börse NasdaqCM

Tickersymbol BNTC

Website https://benitec.com

Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von Benitec Biopharma 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -37.92 Mio, ein Anstieg von 74.32 %.

Finanzberichte

Gewinnüberraschung

Benitec Biopharma hat die Quartalszahlen am May 14, 2026 veröffentlicht:

Umsatz von $0 verfehlt die Erwartungen um $0, mit NaN% Wachstum im Jahresvergleich.

EPS von -0.24 übertrifft die Erwartungen um 0.04, mit 0.00% Wachstum im Jahresvergleich.

Nächste Ergebnisveröffentlichung

Benitec Biopharma Inc. wird voraussichtlich die Quartalszahlen veröffentlichen am Sep 22, 2026, vor Börseneröffnung.
Analysten erwarten einen Umsatz von ... Upgrade

Nachrichten

vor 6 Monaten · Simply Wall St.

Here's Why We're Not At All Concerned With Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

vor 7 Monaten · Zacks

Does Benitec Biopharma (BNTC) Have the Potential to Rally 83.87% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 83.9% in Benitec Biopharma (BNTC). While the effectiveness of this highly sought-after metric is questionable, ...

vor 8 Monaten · Zacks

Wall Street Analysts Predict an 87.48% Upside in Benitec Biopharma (BNTC): Here's What You Should Know

The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 87.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement amo...

vor 8 Monaten · Zacks

Down 25.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Benitec Biopharma (BNTC)

Benitec Biopharma (BNTC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in ...

vor 9 Monaten · Insider Monkey

Citizens Lifts Benitec Biopharma Inc. (BNTC) Price Target on Topline Results for Oculopharyngeal Muscular Dystrophy Treatment

Benitec Biopharma Inc. (NASDAQ:BNTC) is one of the best breakout stocks to invest in. On November 4, an analyst at Citizens JMP raised the stock’s price target to $22 from $20 while reiterating an Out...

Seite 1 von 2

Benitec Biopharma Inc. (BNTC)